|
|
|
29.08.25 - 13:02
|
Telix Pharmaceuticals Aktie: Kursziel nach zweiter FDA-Abfuhr drastisch gesenkt (Aktiencheck)
|
|
MelbourneNew York (www.aktiencheck.de) - Telix Pharmaceuticals-Aktienanalyse von J.P. Morgan Securities:
JPMorgan habe in einer aktuellen Studie die Aktie von Telix Pharmaceuticals Limited (ISIN: AU000000TLX2, WKN: A2H7JK, Ticker-Symbol: T3X, Australian Securities Exchange-Symbol: TLX, NASDAQ OTC-Symbol: TLPPF) nach der zweiten Complete Response Letter (CRL) im Jahr 2025 von "overweight" auf "neutral" abgestuft. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
26.08.25 - 13:03
|
Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire EN)
|
|
MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 4:50 p.m. ET on Monday, September 8, 2025 (6:50 a.m. AEST, Sep 9) and at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. ET on Tuesday, September 9, 2025 (2:00 a.m. AEST, Sep 10)....
|
|
|
|
21.08.25 - 23:12
|
Why Telix shares could rocket 60%+ (Fool)
|
|
Big returns could be on offer here according to analysts at Bell Potter.
The post Why Telix shares could rocket 60%+ appeared first on The Motley Fool Australia....
|
|
|
|
|
|